Study Suggests Mechanism Behind Levodopa-induced Dyskinesia in Parkinson’s

Study Suggests Mechanism Behind Levodopa-induced Dyskinesia in Parkinson’s
The protein RasGRP1 is a key culprit for involuntary movements that arise from dopamine replacement therapies used to treat Parkinson’s disease, a new study done in animals suggests. Targeting this protein may be a therapeutic strategy to prevent these motor problems, while still receiving the benefits of treatment. The study, “RasGRP1 is a causal factor in the development of l-DOPA–induced ... read more
Source: Parkinson’s News TodayPublished on 2020-05-07By Marisa Wexler